With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner
Carmine’s non-viral gene therapy delivery technology offers manufacturing, dosing advantages
Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s first partner Tuesday as the pharma pursues non-viral delivery technologies for pediatric rare genetic diseases.
Carmine Therapeutics Inc. was formed in 2019 with an exclusive license to its foundational vesicle technology that was developed